Discovery & Development COVID-19, Drug Discovery

A Moonshot for COVID-19

Meet the international coalition working to tackle COVID-19 in low- and middle-income countries

Angus Stewart | 10/02/2021 | Quick Read

An open-science consortium fighting for accessible COVID-19 treatments has received £8 million from the Wellcome Trust, a London-based charitable foundation focused on health research. The group, COVID Moonshot, was born in the early days of global lockdown. At that time, an international cross-section of scientists, academics, pharmaceutical research teams, and students began a collaborative race to identify new molecules that could block SARS-CoV-2 infection and to develop pills ready to roll out to those most in need of affordable medicine.

Alpha Lee, of the University of Cambridge, noted that Moonshot’s early efforts – focused on repurposing existing small molecule drugs and rapidly developing monoclonal antibodies – have now shifted to developing new antiviral therapeutics in light of the likely persistence of COVID-19 as a global threat.

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Discovery & Development COVID-19, Drug Discovery

Angus Stewart

Associate Editor of The Medicine Maker

Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.